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In the blurring boundaries between clinical practice and scientific observations, it is increasingly attractive to
propose shared disease mechanisms that could explain clinical experience. With the advent of available therapeutic
options for complement inhibition, there is a push for more widespread application in patients, despite a lack of
clinically relevant research. Patients with disseminated intravascular coagulation (DIC) and thrombotic
microangiopathies (TMA) frequently exhibit complement activation and share the clinical consequences of
thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis. However, they arise from
very different molecular etiologies giving rise to cautious questions about inclusive treatment approaches because
most clinical observations are associative and not cause-and-effect. Complement inhibition is successful in many
cases of atypical hemolytic uremic syndrome, greatly reducing morbidity and mortality of patients by minimizing
thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis. But is this success due to
targeting disease etiology or because complement is a sufficiently systemic target or both? These questions are
important because complement activation and similar clinical features also are observed in many DIC patients, and
there are mounting calls for systemic inhibition of complement mediators despite the enormous differences in the
primary diseases complicated by DIC. We are in great need of thoughtful and standardized assessment with respect
to both beneficial and potentially harmful consequences of complement activation in these patient populations.
In this review, we discuss about what needs to be done in terms of establishing the strategy for complement
inhibition in TMA and DIC, based on the current knowledge.
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The complement and coagulation systems are considered
to be descended from a common ancestral system, more
than 400 million years ago [1,2]. The common feature of
these two cascade systems is that both systems are acti-
vated by common activators or host conditions [3]. Both
systems contain a series of serine protease-mediated reac-
tions, and there is evidence for networking crosstalk with
shared activators and inhibitors. Members of each cascade
interact either directly or indirectly. Upon bacterial infec-
tion, acute blood loss, trauma with tissue injury, malig-
nancy, and many other underlining diseases, both the
coagulation and complement systems are activated in pa-
tients and animal models. If these processes escape from* Correspondence: kurosawa@bu.edu
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unless otherwise stated.their tight and localized control, it may lead to systemic in-
flammatory response syndrome (SIRS) and multiple organ
failure, which is a major contributor to high mortality.Review
Cross talk between complement and coagulation systems
The interplay between the two systems has been studied
for decades [4-7], and this review will highlight the more
current literature (Figure 1). Multiple components of the
complement cascade have the capacity to alter the
phospholipid composition of the outer membranes of
cells. The terminal complement complex (TCC or C5b-9
complex) can flip phosphatidylserine from the internal
leaflet to the cell exterior surface, thereby providing a
negatively charged surface necessary to support the co-
agulation cascade. Complement C3a induces platelet ac-
tivation and aggregation [8]. Before activation, the outersee BioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distri-
vided the original work is properly credited. The Creative Commons Public Do-
ons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Crosstalks between coagulation, fibrinolysis and complement systems. The coagulation cascade is roughly divided into TF pathway
and contact activation. The TF pathway is well known to get activated by TCC, trauma, and some cytokines. Both pathways will merge at FXa level,
which will generate thrombin. Thrombin is one of the most potent activator of platelets. Upon platelet activation, medium-size polyphosphate in the
platelet granules will be released, which can induce contact activation. FXIIa can activate the classical complement pathway. FXIIa can activate plasma
kallikrein, which in turn can activate both C3 and C5. Other members of blood coagulation and fibrinolysis, such as FSAP, thrombin and plasmin can
independently activate both C3 and C5. DAMPs, immune complex and PAMPs are known to activate the classical complement pathway. PAMPs and
apoptotic cells will activate lectin pathway. PAMPs will trigger alternative pathway activation, all leading to C3 activation, which will activate C5. C3a and
C5a will recruit and activate leukocytes, as well as induce platelet activation and aggregation, inducing thrombosis and inflammation, which are known
to further enhance coagulation. C5b will lead to TCC formation, which not only lyse microorganisms but also lyse host cells, which will release DAMPs.
TCC will induce TF pathway, induce platelet activation, and enhance coagulation by negatively charged phospholipid surfaces.
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contain negatively charged phospholipids, whereas abun-
dant phosphatidylserine becomes available after activation
and these surfaces support coagulation. Cell activation will
also release granular contents, which generally enhance
pro-coagulant responses, and release of microparticles will
provide extra surfaces for clot formation.
Binding of C1q to platelets induces the expression of
integrins and P-selectin [9]. The platelet and C1q inter-
action seemed to be more complicated than just moderate
and transient upregulation of P-selectin. Pre-incubation of
platelets with C1q, on the other hand, will diminishcollagen-induced upregulation of P-selectin, but the
pre-incubation is reported to potentiate the collagen-
provoked production of reactive oxygen species. This
paradoxical C1q modulation of platelet that is observed
in vitro may play a significant role in the pathogenesis
of many complement diseases, given that the role of
platelet not only resides in hemostasis but platelet also
interact with white blood cells and modulate immune
and inflammatory reactions.
On endothelial cells, complement effectors will
change the cell properties from anti-coagulant to pro-
coagulant. Complement C5a can induce/increase tissue
Figure 2 Venn diagram of thrombotic microangiopathy and
disseminated intravascular coagulation. As described in the text,
the authors used the term “TMA”, which excludes DIC. The most
popular thrombotic microangiopathy is HUS, which involves Shiga
toxin. Atypical HUS is caused by chronic, uncontrolled, and excessive
activation of complement-inducing platelet activation, endothelial
injury, white cell recruitment, and activation, leading to TMA. Most
cases of TTP arise from inhibition of the enzyme ADAMTS13, a
metalloprotease responsible for cleaving large multimers of von
Willebrand factor. A rare form of TTP is caused by genetically inherited
dysfunction of ADAMTS13. This form is called Upshaw-Schülman
syndrome. DIC is not a distinct disease entity. It occurs as a
secondary complication of many different disorders, including sepsis,
trauma, cancer, obstetric complications, and others.
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thelial cells [10], and TCC or C1q will upregulate sev-
eral adhesion molecules.
Thrombin, the end-product of the coagulation cas-
cade, has considerable capacity to accelerate activation
of both pathways by forming positive feedback loops.
Thrombin generates C5a, a powerful anaphylatoxin, in
C3 null mice lacking C3 convertase [11], and C5a in-
duces tissue factor activity on human umbilical vein
endothelial cells. Similarly, immunoblockade of C5 activa-
tion reduces microparticle-associated tissue factor activity
and antigen as a consequence of Neisseria meningitides,
the cause of bacterial meningitis [12]. Activation of com-
plement was shown to decrypt encrypted tissue factor
[13]. Activation of platelets will induce its granular release.
One of the most abundant substances is polyphosphate.
Platelet polyphosphate is much shorter than microbial
long-chain polyphosphate, and platelet polyphosphate
is demonstrated to exert contact activation of blood co-
agulation [14].
Kallikrein and factor XIIa can cleave complement
components. Plasmin, the most powerful serine protease
of the fibrinolytic system, was also shown to be capable
of cleaving both C3 and C5, and the cleavage products
are biologically active [15].
Factor VII-activating protease (FSAP), also known as
plasma hyaluronan binding protein, is a circulating serine
protease believed to activate blood coagulation factor VII
and single-chain pro-urokinase [16], although activa-
tion of factor VII is questioned [17]. FSAP zymogen is
notoriously unstable and can be activated by histones
and nucleosomes arising from necrotic or apoptotic
cells. Trauma patients have high levels of these circulat-
ing damage-associated molecular pattern (DAMPs)
molecules, and FSAP is activated in patients with multiple
traumas [18]. Complement proteins form complexes with
FSAP and FSAP can cleave C3 and C5 to generate the C3a
and C5a anaphylatoxins [15].
In addition to the direct molecular links between the
coagulation and complement systems, both systems are
intimately linked to inflammation. Activation of the
complement and coagulation systems is capable of inde-
pendently augmenting inflammatory responses, which in
turn can potentiate both complement and coagulation
activation. Endothelial cells play major roles in inflam-
mation, including endothelial cell activation and injury/
dysfunction. Given the abundant cross talk between co-
agulation and complement systems, it seems unlikely
that one will be activated without the other. The expect-
ation is that complement will be activated in almost all
thrombotic disorders, including DIC and TMA, both of
which can develop with thrombocytopenia, microangio-
pathic hemolytic anemia, and microvascular thrombosis.
Thus, some groups of experts in the field place DIC inthe list of TMA in a broader sense. However, in this article,
DIC will be considered to be distinct from the TMAs and
will be included in the list of differential diagnoses because
most cases are distinguishable based on clinical presen-
tation and laboratory findings (Figure 2). However, as
occurs many times in clinical practice, these grouping
designations still present a challenge in a small number
of patients, especially in the presence of overlapping
clinical features.
Thrombotic microangiopathy
TMA involves several distinct etiologic pathological pro-
cesses, but with shared clinical features that include
thrombocytopenia, microangiopathic hemolytic anemia,
and microvascular thrombosis, leading to end-organ ische-
mia, infarction, and dysfunction. The most common TMA
is due to hemolytic uremic syndrome (HUS), caused by
Shiga toxin (Stx)-producing enterohemorrhagic Escheri-
chia coli (EHEC). Infection with this toxigenic intestinal
pathogen is a leading cause of acute renal failure in other-
wise healthy children. EHEC can produce two Shiga-like
exotoxins, Stx1 and Stx2, which are primary virulence
factors causing organ injury [19]. These are ribosome-
inactivating toxins, named after Dr. Kiyoshi Shiga, a pio-
neering clinical microbiologist born in Sendai, who made
the landmark discovery at the turn of the 20th century that
“toxic factors” from Shigella dysenteriae cause the clinical
manifestations of bacillary dysentery (sekiri) [20]. Shiga
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toxins, and Stx1 from EHEC differs by only one amino
acid. Stx2 shares 56% amino acid sequence identity with
Stx1, and the toxins are antigenically distinct [21]. Many
clinical and animal studies have shown that Stx is neces-
sary and sufficient for causing HUS, and for reasons that
are not well understood, Stx2 is associated with more se-
vere clinical consequences. Other, more rare, causes of
TMA-associated HUS include invasive pneumococcal in-
fection in pediatric patients [22,23], atypical HUS, throm-
botic thrombocytopenic purpura (TTP), and others.
HUS
HUS arising during EHEC infection is a global public
health problem. The massive EHEC outbreak due to
contaminated school lunches in over 12,000 symptom-
atic adults and children in Sakai City, Osaka, Japan, in
1996 is one of the largest outbreaks known [24]. During
the spring and summer of 2011, there was an outbreak
of hemorrhagic colitis and HUS in Europe, originating
in Germany, involving more than 4,000 cases, 852 pa-
tients with HUS and 54 deaths. It was caused by bean
sprouts contaminated with an enteroaggregative E. coli
strain that had acquired the ability to produce Stx2 [25].
Argentina has arguably the highest incidence of EHEC
infection and pediatric HUS [26,27] and contaminated
ground beef, water, fresh produce, and other foods that
causes recurrent global public health problems. Accord-
ing to the US Centers for Disease Control and Preven-
tion, the human burden is approximately 110,000
infections annually in the United States alone [28] and
is estimated at approximately 1.5 million cases globally
with 3%–5% mortality and significant morbidity, including
impaired renal function, hypertension and cardiovascular
diseases, pre-eclampsia, and other complications.
Clinically, HUS from any etiology includes a throm-
botic component and is considered to be a TMA and
distinct from DIC. However, DIC and TMA share exten-
sive features, including thrombocytopenia, microvascular
thrombosis, microangiopathic hemolytic anemia, and
organ dysfunction, such as acute kidney injury. This is
why some groups prefer to include DIC in the list of
TMAs. In order to dissect the differences and similar-
ities between DIC and TMA, the simplest approach is to
examine animal models of TMA and DIC. Although
there are multiple DIC animal models, animal models of
TMA have significant challenges when the goal is to re-
capitulate human responses.
Injection of Stx into mice results in acute kidney injury
but, unlike humans, the Stx challenge does not cause
thrombocytopenia or TMA. This is thought to be due to
the fact that murine glomerular endothelial cells do not
express globotriaosylceramide (Gb3) glycolipid, the re-
ceptor for Shiga toxin [29]. As a result, glomerulopathyis not the main pathology in mice Stx model. Instead,
mouse renal tubular cells express the receptor, leading to
direct tubular lesions and kidney dysfunction. The mouse
Stx model is a very good model for screening compounds
that will neutralize Stx, for example. However, the mouse
Stx model is not a good model for studying TMA because
Stx does not cause TMA in mice. In order to circumvent
this shortcoming, a murine Stx + LPS model was pro-
posed, in which LPS is co-administered together with Stx
[30]. This model does show complement activation,
thrombocytopenia, and glomerulopathy, which are missing
in the mouse Stx model, and there has been inferences
that LPS must be a critical component in humans because
it is true in mice. Unfortunately, most researchers in the
field of EHEC-HUS have limited clinical or research ex-
perience with DIC. It has been well established for decades
that LPS activates complement and causes DIC in animals
and humans [31] and is clinically distinct from HUS.
Complement is activated in the LPS + Stx murine
model and that coupled with evidence of complement in
some EHEC patients [32] further suggested that comple-
ment must be driving the TMA in HUS.
Atypical HUS
Atypical HUS is a very rare progressive and life-
threatening disease. Most patients have genetic abnor-
malities in the complement system, with most of the
mutations found in the regulatory molecules of comple-
ment activation. It is thought that chronic, uncon-
trolled, and excessive activation of complement causes
platelet activation, endothelial injury, white cell recruit-
ment, and activation, all of which lead to TMA.
The role of complement activation in atypical HUS is
very well established. The end results produce essen-
tially the same clinical features, including consumptive
thrombocytopenia, microangiopathic hemolytic anemia,
microvascular thrombosis, and TMA, with the exception
of the time course. There is a treatment available, and it is
very effective. The drug is called Eculizumab™, a human-
ized monoclonal antibody to complement 5 (C5). By bind-
ing to C5 and inhibiting its activation, the antibody
ultimately prevents terminal complement complex (TCC)
formation, providing the needed regulation of the comple-
ment pathway.
Is Stx-HUS driven by complement activation?
Since both HUS and aHUS present with reasonably
similar clinical parameters, except for time course, in
combination with the observation that complement is
activated in the murine Stx + LPS co-injection model,
there is thinking that complement activation is the com-
mon driver of coagulopathy in HUS, atypical HUS, and
DIC [32]. This approach is intended to explain why HUS
and atypical HUS have overlapping clinical presentations
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hemolytic anemia, microvascular thrombosis, and TMA.
Moreover, some patients with EHEC infection and HUS
show evidence of complement activation. However,
while there is no doubt that complement regulation is
the villain in atypical HUS, the actual evidence for com-
plement as a primary mediator of HUS or TTP is weak.
Eculizumab™ was approved for off-label use on a compas-
sionate basis for use in a sub-group of patients with particu-
larly refractory HUS during the 2011 EHEC outbreak in
Europe (University Hospital of Bordeaux Regional Ethics
Committee, and AFSSAPS). The results were mixed. While
it is clear that the drug can be safely used in patients with
HUS, it was not clear whether the treatment was effective
or not [33]. This was a study done under remarkable condi-
tions, performed in the middle of a public health emergency
in several countries, so control groups were not possible
and efficacy was difficult to conclude.
The question of complement involvement in HUS
continues in part because there is no specific treatment
available, other than general intensive supportive care, in-
cluding dialysis and administration of intravenous fluids
[34]. If complement activation plays a major role in HUS,
then Eculizumab™ has the potential to become the first
drug for the treatment of HUS associated with EHEC.
Since EHEC-HUS is the most frequent among TMAs, spe-
cific treatment will be well received by patients, families,
and physicians. Proof of efficacy would require random-
ized double-blind placebo controlled clinical trials which
will be very expensive and need a substantial commitment,
given that most patients will be children and will present
with acute and emergency courses. Even though the inci-
dence of EHEC infection is estimated to be about 110,000
annually in the US, or 1.5 million globally, these are usu-
ally small outbreaks and the expected number of patients
per one health care facility is typically small. A clinical trial
will require many centers and a long period of time, fur-
ther adding more costs. To make the matters even worse,
HUS occurs in only about approximately 8% of EHEC
cases, increasing the necessary enrollment number expo-
nentially to the point that investors will be reluctant due
to the limited market share and a limited return on a ne-
cessary substantial investment.
Non-human primate model of Stx-HUS
To help relieve this bottleneck, our laboratory asked the
question of whether complement activation is required for
the development of HUS. We used our non-human primate
(NHP) model of Stx-induced HUS. The baboons receive a
single intravenous bolus injection of Stx1 or Stx2, and devel-
opment of pathophysiology is monitored over time [35].
The initial dose response study revealed that Stx1 at 10 ng/
kg elicited mild transient changes; 50 ng/kg was severe (4/5
euthanized), and 100 ng/kg was lethal (5/5 euthanized). Thedose-response for Stx2 could also be titrated, but the con-
centration range differed with a lethal dose at 50 ng/kg
Stx2 (6/6 euthanized). Subsequent studies revealed that
there are significant differences between the toxins in
timing, inflammation responses, and kidney pathology,
but they share the ability to induce HUS [36-38].
Thrombocytopenia is one of the hallmarks of HUS,
monitored closely in patients, and we also find platelet
levels to be a good marker of disease onset and severity
in the baboon models. In our model, both Stx1 and Stx
2 induced thrombocytopenia in a dose-dependent man-
ner in all subjects. The levels of blood urea nitrogen
(BUN) also increased dose dependently. Microscopic
examination of the kidneys revealed microthrombi in
the glomerular capillary, mostly made up of platelets or
platelets and RBC [36]. Glomerular endothelial cells
were lost or markedly swollen, with frequent fibrin de-
position on the luminal side of basement membrane in
the renal glomerular capillaries. D-dimer levels increase
indicating that both coagulation and fibrinolysis takes
place. In plasma and urine, we measured two damage-
associated molecular patterns markers of cell injury,
HMGB1 and histones, and found that both are elevated
in our model of Stx-HUS, yet complement was not acti-
vated [38]. We measured plasma TCC levels and found
no increase despite development of HUS and renal in-
jury, indicating that there is no substantial complement
activation throughout the entire course of developing
HUS pathophysiology. This demonstrates that comple-
ment activation is not required for the development of
HUS. The lack of complement activation in the Citro-
bacter rodentium-Stx2 murine model, which has an in-
testinal bacteria secreting Stx2 [39], is supportive of this
notion, but again, the mice do not develop TMA. The
baboon studies are limited by the fact that the baboons
receive a single Stx challenge, rather than prolonged ex-
posure to toxin from an enteric bacterial infection, and
humans might just simply differ in response.
Complement activation in DIC
In contrast to the baboon HUS model, plasma TCC levels
elevate rapidly after intravenous challenge of baboons with
Gram-negative or Gram-positive bacteria [38]. These
bacteremia sepsis models are also consistent and repro-
ducible models of DIC [40]. D-dimer increases, fibrino-
gen is consumed, and clotting times prolong. Similar to
bacteremia, multiple trauma injuries are known to in-
duce rapid activation of complement in humans [41,42].
Since we know that uncontrolled activation of comple-
ment can induce atypical HUS, and that there is sub-
stantial complement activation in DIC models [43] as
well as patients, it is conceivable that DIC patients may
suffer the same pathology as that observed in patients with
atypical HUS, in addition to DIC-specific pathology. Also,
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tween each DIC patient. Since atypical HUS involves
thrombocytopenia, microangiopathic hemolytic anemia,
and acute kidney injury, there is a real possibility that
Eculizmab™ may provide at least partial relief in certain
sub-groups of DIC patients, including maybe burn in-
jury patients [44].
It has been well over 100 years since complement was
discovered. Complement activation in patients with DIC
is well known, as is the crosstalk between the comple-
ment and coagulation systems. Given this networking,
complement is activated in most patients with DIC, in
which coagulation is most always activated. Due to the
fact that complement is an immutable part of innate im-
munity involved in pathogen sensing, opsonization, and
clearance, patients with infections may not be a good
target population for a complement inhibiting strategy
because we do not want to compromise innate immune
response while the patients are trying to fight off the in-
fections. However, the literature is conflicting, and
whether C5b-9 is protective or detrimental remains to
be determined [45]. Complement activation seemed less
pronounced in isolated models of ischemia and reperfu-
sion, whereas the responses are stronger in hemorrhagic
trauma shock and multiple trauma injury models. The
combination of traumatic brain injury and shock results
in an immediate activation of coagulation and comple-
ment systems [46]. In humans, a number of reports indi-
cate that the pathogenesis of spinal cord injury involves
not only by primary mechanical trauma but also by sec-
ondary response, including complement activation [47].
Complement activation has been associated with acute
neuroinflammation and secondary brain injury after se-
vere trauma [48]. Mice lacking the receptors CR2/CD21
and CR1/CD35 are protected from adverse sequelae of
experimental closed head injury [49].
Complement inhibitors, current and future
Eculizmab™ is already in the market and several clinical tri-
als for a variety of complement-driven diseases are on-
going [50]. Anti-C5a was shown to ameliorate coagulation
and fibrinolytic changes in a rat model of sepsis [51]. C1
inhibitor may have a beneficial effect in a primate sepsis
model [52]. Several other complement inhibitors are under
development. TT30 is a novel therapeutic fusion protein
linking the C3 fragment-binding domain of human
complement receptor type 2 (CR2/CD21) with the com-
plement alternative pathway inhibitory domain of hu-
man factor H [53]. TT30 is designed to deliver cell
surface-targeted regulation of the alternative pathway
activity. It blocks ex vivo hemolysis of paroxysmal noc-
turnal hemoglobinuria erythrocytes, while at the same
time retaining the normal ability of the complement
system to efficiently activate C3 through the classicaland lectin pathways. The murine analog of TT30 was
able to attenuate collagen-induced arthritis, systemic
lupus erythematosus, and tissue injury [54]. Finally,
anti-C3b/iC3b monoclonal antibody 3E7 can block both
complement-mediated hemolysis and C3 deposition in
an in vitro model of alternative pathway-mediated
hemolysis [55].
The urgent question is: can complement activation
in DIC be a target for treatment or not? Given that
Eculizmab™ is already in the market, and many other
complement inhibitors are in the short pipeline, the
question needs to be answered rather quickly. We
would like to come to the correct answer, preferably
with ample evidences using pre-clinical DIC models,
before application to humans. The problem is that we
do not have ample evidences available at this point. It
is highly unlikely that it will be a simple yes/no answer
that will apply to all DIC patients. Our prediction is
that it probably depends on cases, timing, and every-
thing else. So the question will most likely become
“which subcategory of patients with DIC will benefit, and
which will not?” These types of questions will demand an
enormous amount of data to make successful translation.Conclusions
Complement activation is observed in certain groups of
TMA patients, as well as many patients with DIC. As the
therapeutic options are expanding, more questions arise as
to which patients may benefit from complement-targeted
treatments. Since the complement pathway constitutes
one of the most important innate immune effectors, it be-
comes critical to assess the role and the extent of comple-
ment activation in each patient. In order to get there, we
need to study the extent of complement involvement in
HUS, DIC, and TMA in pre-clinical animal models, as
well as developing diagnostic methods for the assessment
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